About AngioDynamics (NASDAQ:ANGO)
AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company's Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company's BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Supplies
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:ANGO
- CUSIP: 03475V10
- Web: www.angiodynamics.com
- Market Cap: $646.94 million
- Outstanding Shares: 36,715,000
- 50 Day Moving Avg: $17.45
- 200 Day Moving Avg: $16.38
- 52 Week Range: $14.80 - $18.85
Sales & Book Value:
- Trailing P/E Ratio: 177.98
- Foreward P/E Ratio: 23.81
- P/E Growth: 1.92
- Annual Revenue: $346.96 million
- Price / Sales: 1.86
- Book Value: $13.99 per share
- Price / Book: 1.26
- EBITDA: $47.67 million
- Net Margins: 1.64%
- Return on Equity: 4.83%
- Return on Assets: 3.57%
- Debt-to-Equity Ratio: 0.17%
- Current Ratio: 2.34%
- Quick Ratio: 1.48%
- Average Volume: 240,734 shs.
- Beta: 1.12
- Short Ratio: 7.79
Frequently Asked Questions for AngioDynamics (NASDAQ:ANGO)
What is AngioDynamics' stock symbol?
AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."
How were AngioDynamics' earnings last quarter?
AngioDynamics, Inc. (NASDAQ:ANGO) announced its earnings results on Thursday, September, 28th. The company reported $0.12 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.16 by $0.04. The business earned $85.40 million during the quarter, compared to analyst estimates of $86.12 million. AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. The business's quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.17 earnings per share. View AngioDynamics' Earnings History.
When will AngioDynamics make its next earnings announcement?
What guidance has AngioDynamics issued on next quarter's earnings?
AngioDynamics updated its FY18 earnings guidance on Thursday, September, 28th. The company provided earnings per share (EPS) guidance of $0.64-0.68 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.67. The company issued revenue guidance of $352-359 million, compared to the consensus revenue estimate of $355.58 million.
Where is AngioDynamics' stock going? Where will AngioDynamics' stock price be in 2017?
5 brokerages have issued twelve-month price objectives for AngioDynamics' shares. Their predictions range from $16.00 to $21.00. On average, they expect AngioDynamics' share price to reach $18.50 in the next twelve months. View Analyst Ratings for AngioDynamics.
What are analysts saying about AngioDynamics stock?
Here are some recent quotes from research analysts about AngioDynamics stock:
- 1. According to Zacks Investment Research, "AngioDynamics reported a dismal first quarter of fiscal 2018 wherein adjusted earnings and revenues missed the Zacks Consensus Estimate. The company reaffirmed its guidance for fiscal 2018. AngioDynamicis rides on the market’s solid response to Solero, especially within the Microwave Ablation space. Growth in the core Angiographic Catheter business is also likely to fortify the company’s footprint in the global space. On the flipside, AngioDynamics recalled the Acculis Microwave Tissue Ablation System under the Oncology and Surgery segment last quarter. The company also had a high outstanding debt level at the end of the first quarter. Higher debts impose certain operating and financial restrictions which might limit the execution of the company’s core business strategies. AngioDynamics traded below the broader industry in the past year." (10/3/2017)
- 2. Cantor Fitzgerald analysts commented, "F3Q17 Result Summary. F3Q17 total revenues of $85.6M (down 2.0% y/y), was $3.2M below our estimate of $88.8M and $2.7M below FactSet consensus of $88.3M." (3/30/2017)
Who are some of AngioDynamics' key competitors?
Some companies that are related to AngioDynamics include Repligen Corporation (RGEN), Ascendis Pharma A/S (ASND), Varex Imaging (VREX), Acorda Therapeutics (ACOR), Zogenix (ZGNX), LHC Group (LHCG), Akcea Therapeutics (AKCA), Esperion Therapeutics (ESPR), IRHYTHM TECH (IRTC), OraSure Technologies (OSUR), Dermira (DERM), Lexicon Pharmaceuticals (LXRX), The Ensign Group (ENSG), Genomic Health (GHDX), Glaukos Corporation (GKOS), Epizyme (EPZM), Sangamo Therapeutics (SGMO) and Dynavax Technologies Corporation (DVAX).
Who are AngioDynamics' key executives?
AngioDynamics' management team includes the folowing people:
- Howard W. Donnelly, Independent Chairman of the Board
- James C. Clemmer, President, Chief Executive Officer, Director
- Michael Greiner, Chief Financial Officer, Executive Vice President
- Gary Barrett, Senior Vice President,Quality and Regulatory Affairs
- Ben Davis, Senior Vice President, Business Development
- Barbara Kucharczyk, Senior Vice President-Global Operations
- Stephen A. Trowbridge, Senior Vice President, General Counsel
- Eileen O'Shea Auen, Director
- Jan Stern Reed, Director
- David F. Burgstahler, Independent Director
How do I buy AngioDynamics stock?
Shares of AngioDynamics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AngioDynamics' stock price today?
MarketBeat Community Rating for AngioDynamics (NASDAQ ANGO)MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of AngioDynamics stock can currently be purchased for approximately $17.62.
Consensus Ratings for AngioDynamics (NASDAQ:ANGO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Hold Ratings, 2 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.40)|
|Consensus Price Target: ||$18.50 (4.99% upside)|Consensus Price Target History for AngioDynamics (NASDAQ:ANGO)
Analysts' Ratings History for AngioDynamics (NASDAQ:ANGO)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/8/2017||Canaccord Genuity||Reiterated Rating||Hold||$17.00||N/A|
|7/19/2017||Barclays PLC||Lower Price Target||Equal Weight||$17.00 -> $16.00||Low|
|7/4/2017||Cantor Fitzgerald||Boost Price Target||Overweight||$20.00 -> $21.00||Low|
|4/1/2017||Craig Hallum||Set Price Target||Buy||$20.00||Low|
|4/8/2016||Piper Jaffray Companies||Initiated Coverage||Neutral||$12.00||N/A|
|11/10/2015||Raymond James Financial, Inc.||Downgrade||Outperform -> Market Perform||N/A|
Earnings History for AngioDynamics (NASDAQ:ANGO)Earnings History by Quarter for AngioDynamics (NASDAQ ANGO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/28/2017||Q1 2018||$0.16||$0.12||$86.12 million||$85.40 million||View||N/A|
|7/18/2017||Q4 2017||$0.16||$0.19||$90.72 million||$86.90 million||View||N/A|
|3/30/2017||Q3 2017||$0.15||$0.19||$88.29 million||$85.60 million||View||N/A|
|1/6/2017||Q217||$0.16||$0.19||$91.09 million||$89.00 million||View||Listen|
|10/5/2016||Q117||$0.13||$0.17||$86.09 million||$88.10 million||View||N/A|
|7/13/2016||Q416||$0.16||$0.19||$88.64 million||$93.40 million||View||Listen|
|4/7/2016||Q3||$0.14||$0.15||$85.43 million||$87.40 million||View||Listen|
|1/7/2016||Q216||$0.14||$0.14||$88.67 million||$89.20 million||View||N/A|
|10/8/2015||Q116||$0.11||$0.11||$84.70 million||$83.70 million||View||N/A|
|7/16/2015||Q415||$0.14||$0.14||$91.67 million||$90.90 million||View||Listen|
|4/9/2015||Q315||$0.15||$0.12||$88.69 million||$86.60 million||View||N/A|
|1/8/2015||Q215||$0.15||$0.17||$90.90 million||$92.10 million||View||N/A|
|10/9/2014||Q115||$0.11||$0.16||$85.35 million||$87.30 million||View||Listen|
|7/23/2014||Q414||$0.12||$0.18||$93.65 million||$94.07 million||View||Listen|
|4/9/2014||Q314||$0.09||$0.16||$86.85 million||$88.20 million||View||Listen|
|1/9/2014||Q2||$0.07||$0.14||$87.54 million||$88.60 million||View||Listen|
|10/10/2013||Q114||$0.03||$0.04||$82.54 million||$83.60 million||View||N/A|
|7/11/2013||Q4 2013||$0.06||$0.07||$86.43 million||$90.00 million||View||N/A|
|4/8/2013||Q3 2013||$0.05||$0.08||$81.70 million||$81.60 million||View||N/A|
|1/3/2013||Q2 2013||$0.09||$0.10||$87.40 million||$87.00 million||View||N/A|
|10/8/2012||Q113||$0.09||$0.10||$84.35 million||$83.40 million||View||N/A|
Earnings Estimates for AngioDynamics (NASDAQ:ANGO)
2017 EPS Consensus Estimate: $0.61
2018 EPS Consensus Estimate: $0.71
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for AngioDynamics (NASDAQ:ANGO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for AngioDynamics (NASDAQ:ANGO)
Insider Ownership Percentage: 1.80%Insider Trades by Quarter for AngioDynamics (NASDAQ:ANGO)
Institutional Ownership Percentage: 95.42%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/24/2017||Jan Stern Reed||Director||Buy||316||$16.00||$5,056.00|| |
|7/21/2017||James C Clemmer||CEO||Buy||5,000||$15.79||$78,950.00|| |
|7/20/2017||James C Clemmer||CEO||Buy||20,000||$15.64||$312,800.00|| |
|4/12/2017||Avista Capital Partners Gp, Ll||Major Shareholder||Sell||2,350,000||$16.00||$37,600,000.00|| |
|8/5/2016||Avista Capital Partners Gp, Ll||Major Shareholder||Sell||2,241,000||$14.62||$32,763,420.00|| |
|8/5/2016||David F Burgstahler||Director||Sell||2,250,000||$14.62||$32,895,000.00|| |
|5/6/2016||Charles R Greiner||VP||Sell||3,508||$12.31||$43,183.48|| |
|4/25/2016||Stephen A Trowbridge||SVP||Sell||12,940||$12.30||$159,162.00|| |
|4/14/2014||Matthew Kapusta||SVP||Buy||1,000||$13.90||$13,900.00|| |
|10/18/2013||Vincent Bucci||Director||Buy||5,000||$15.20||$76,000.00|| |
|10/17/2013||Howard W Donnelly||Director||Sell||20,000||$15.06||$301,200.00|| |
|7/22/2013||Kevin J Gould||Director||Buy||2,700||$12.00||$32,400.00|| |
|5/9/2013||Charles R Greiner||VP||Sell||1,495||$10.38||$15,518.10|| |
|3/12/2013||Vincent Bucci||Director||Buy||85,000||$10.77||$915,450.00|| |
|2/14/2013||Vincent Bucci||Director||Buy||2,000||$12.17||$24,340.00|| |
|1/11/2013||Kevin J Gould||Director||Buy||2,700||$11.58||$31,266.00|| |
|11/5/2012||Jeffrey Gold||Director||Buy||1,000||$10.56||$10,560.00|| |
Headline Trends for AngioDynamics (NASDAQ:ANGO)
Latest Headlines for AngioDynamics (NASDAQ:ANGO)
Loading headlines, please wait.
AngioDynamics (ANGO) Chart for Sunday, October, 22, 2017